In the Netherlands, the crude rate for breast cancer mortality has fallen from 44.9 to 37.8 death cases per 100 000 in the past two decades, and nowadays the 5-year age-adjusted relative survival is 82% ([@bib17]). Around 10% of all breast cancer patients will develop metastatic breast cancer (MBC) within 5 years after primary diagnosis ([@bib20]). The incidence of MBC is highest in the first 2 years, slowly decreases till the fifth year and remains relatively constant thereafter ([@bib24]; [@bib20]). The most common sites for MBC are bone, lung/pleura, liver, lymph nodes and brain ([@bib24]; [@bib36]; [@bib20]).

According to the clinical guidelines of the European Society for Medical Oncology and the National Comprehensive Cancer Network ([@bib28]), the standard work-up for diagnosing MBC includes conventional imaging with bone X-ray and/or bone scintigraphy, chest X-ray and/or chest computed tomography (CT), liver ultrasound and/or abdominal CT, and magnetic resonance imaging (MRI). Histological biopsies are advised to confirm findings and re-evaluate tumour receptor status of MBC (oestrogen receptor (ER), progesterone receptor, human epidermal growth factor receptor 2 (HER2; [@bib2]; [@bib28]). However, biopsies can be difficult to obtain owing to the location of the metastasis and results can be inconclusive regarding the receptor status, which hampers optimal treatment ([@bib14]).

When findings on conventional imaging are equivocal or in locally advanced inoperable breast cancer, positron emission tomography (PET) and CT (PET/CT) with 2-\[^18^F\]fluoro-2-deoxy-D-glucose (FDG) is an acceptable option to further evaluate suspected MBC ([@bib11]; [@bib2]; [@bib28]; [@bib3]).

Positron emission tomography imaging with the novel tracer 16*α*-\[^18^F\]fluoro-17*β*-oestradiol (FES) can give insight in tumour ER expression in breast cancer ([@bib31]), and has high sensitivity for bone (92%) and lung lesions (95% [@bib37]). FES-PET was found to improve the diagnosis and treatment decision making in patients with a history of ER-positive breast cancer presenting with a clinical dilemma on conventional imaging ([@bib38]). It should be noted that a negative FES-PET does not rule out tumour, as ER-negative metastases are not visible on FES-PET. The combination of FES-PET and CT may, however, largely overcome this issue by giving insights in tumour lesions on CT that are FES negative. To our knowledge, the effect of upfront PET/CT with the tracers FES and FDG on the number of performed biopsies and associated costs has so far not been examined.

The aim of this study was, therefore, to evaluate the effect on the number of performed biopsies and costs associated with implementing FES or FDG-PET with contrast-enhanced CT as an upfront imaging test for diagnosing ER-positive MBC in comparison with the standard work-up in women presenting with symptoms.

Materials and Methods
=====================

A previously published and validated computer simulation model was extended and validated to reflect diagnosing of MBC ([@bib18]; [@bib12]; [@bib21]; [@bib6]). The model was constructed to simulate the follow-up of women after a diagnosis of initial breast cancer with ER-positive receptor status of the primary tumour. The main outcome was the number of avoided biopsies.

The Medical Ethical Committee of the University Medical Center Groningen concluded that no formal approval for this project was needed, as it was not a medical research study that involved humans. Informed consent from patients was not needed.

Structure of the model
----------------------

The structure of the simulation model and its parameters are presented in [Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"} and [Tables 1](#tbl1){ref-type="table"} and [2](#tbl2){ref-type="table"}. Every year a woman might die, might develop symptoms and MBC or might develop symptoms suggestive for MBC without actual disease. The model first evaluated whether a woman would die, using age and general death rate. In case of death, the woman exited the loop. Otherwise, the presence of MBC was simulated based on the risk to develop MBC over time and distributed over the four locations. If MBC was present, the woman developed symptoms at the specific location(s) of the MBC(s). However, if no MBC was present, symptoms suggestive for MBC could still be present depending on the risk to develop such symptoms per year ([Table 1](#tbl1){ref-type="table"}). In the absence of symptoms, the woman\'s age was increased by 1 year and the loop was repeated. If presenting with symptoms, with or without underlying MBC, the woman was subjected to a diagnostic strategy. When actual MBC was diagnosed (as confirmed by a positive biopsy or a positive FES-PET/CT) the woman exited the simulation. If the woman was not diagnosed with MBC, either due to false symptoms or false-negative test results, her age was increased and she re-entered the loop.

Strategies for detecting MBC
----------------------------

Three diagnostic strategies for detecting symptomatic MBC were compared ([Figures 1](#fig1){ref-type="fig"}, [2](#fig2){ref-type="fig"}, [3](#fig3){ref-type="fig"}). The standard work-up was based on the Dutch clinical guidelines and included the recommended tests, that is, X-ray, bone scintigraphy, CT, ultrasound, MRI and biopsies ([@bib23]; [Figure 1](#fig1){ref-type="fig"}).

In the FES-PET/CT strategy, whole-body FES-PET/CT replaced the conventional imaging tests as upfront diagnostic for symptomatic MBC. In case of positive FES-PET/CT, no biopsy procedures were performed. When the FES-PET/CT was negative and there were no longer (at 3 months) symptoms suggestive for MBC, the patients exited the loop without further testing. In case of negative or inconclusive FES-PET/CT and persistent MBC symptoms, conventional imaging and biopsies were added to exclude the option of ER-negative MBC ([Figure 2](#fig2){ref-type="fig"}).

In the FDG-PET/CT strategy, patients followed the same route and diagnostic sequence as in the FES-PET/CT, but whole-body FDG-PET/CT was the upfront diagnostic test. As the FDG-PET/CT was not informative of the MBC receptor status, biopsies still had to be performed in case of positive FDG-PET/CT ([Figure 3](#fig3){ref-type="fig"}).

The parameters of the model
---------------------------

The model incorporated seven parameters ([Table 1](#tbl1){ref-type="table"}) with distinctive baseline, minimum and maximum estimates derived from literature. The risk to develop MBC and the incidence distribution was calculated from a study including 6644 patients diagnosed with breast cancer in the period 2001--2002 and followed till the end of 2007 ([@bib20]). The yearly risk to develop symptoms suggestive for MBC and its distribution over the four locations was based on the observed referral rate to diagnostic services in primary care cancer survivors, which could be considered a good proxy for the incidence of such symptoms in this population ([@bib34]; [@bib4]). The death rate model was based on the cumulative death rates at ages up to 100 years for the Dutch cohort born in 1970 ([@bib21]; [@bib6]). The model contained the mean sensitivity and specificity of the imaging modalities independent of age ([Table 2](#tbl2){ref-type="table"}; [@bib32]; [@bib39]; [@bib7]; [@bib22]; [@bib5]; [@bib9]; [@bib13]; [@bib8]; [@bib15]; [@bib26]; [@bib16]; [@bib27]; [@bib35]). The specificity of FES-PET was based on earlier studies that compared FES-uptake with tumour biopsies, with either qualitative assessment of FES-uptake or quantitative assessment with a maximum standardised uptake value (SUV~max~) threshold of ⩾1.0 ([@bib37]). The inconclusive rates of imaging tests and biopsies were based on expert opinion.

The model validation
--------------------

To validate the model, a cohort of all female patients diagnosed and treated with ER-positive primary breast cancer in the period 2000--2002 at our hospital was identified (*n*=108) and followed for 5 years.

The simulation
--------------

To evaluate the strategies for detecting MBC, a cohort of women treated for primary breast cancer was simulated. The ages of breast cancer diagnosis in this cohort were derived from a cohort of 5073 women diagnosed with and treated for breast cancer between January 1989 and January 2003 in four hospitals in the Netherlands (one academic hospital, one large teaching hospital and two non-teaching hospitals). The women were representative for the Dutch breast cancer population with respect to their age at diagnosis (61.1±14.4 years; [@bib21]).

Sensitivity analysis
--------------------

A sensitivity analysis was performed to test the effect of the uncertainty regarding input estimates on model output. A normal distribution of all parameters was assumed with minimum and maximum estimates equal to the 95% confidence interval around the baseline. For each parameter, a random value was obtained from the normal distribution. The simulations for the three scenarios were performed with 10 data sets for 5073 women and for 20 simulation rounds. For the validation, the simulation data was scaled to represent the outcomes for 108 women. All outcomes were presented in terms of mean and s.d. ([Tables 3](#tbl3){ref-type="table"} and [4](#tbl4){ref-type="table"}).

Costs
-----

Cost parameters included the unit prices of the tests based on tariffs ([Table 2](#tbl2){ref-type="table"}; [@bib29]). The price level of 2013 was applied and valued in Euros (ɛ). Only direct costs related to diagnosing MBC were considered. Discounting was not applied.

Economic analysis of model outcomes
-----------------------------------

The total costs for the strategies were computed by summing the costs of all performed tests. The incremental cost-effectiveness ratio (ICER) was calculated by dividing the additional costs of the alternative strategies resulting from initial imaging and staging tests by the number of avoided biopsies.

Results
=======

Validation of the model
-----------------------

The simulation model reproduced sufficiently the number of initial tests and biopsies, whose actual observed values were in the models\' confidence intervals (104.0±6.5 *vs* 116 and 20.3±1.5 *vs* 18). The model slightly overestimated the staging tests (17.9±1.3 *vs* 13) and underestimated the MBCs (10.2±1.0 *vs* 14; [Table 3](#tbl3){ref-type="table"}).

Clinical effects
----------------

The replacement of the standard testing by FES-PET/CT decreased the total number of biopsies by 39±9% as compared with the standard work-up, whereas the FDG-PET/CT increased the number of biopsies by 38±15% in comparison with standard care.

The number of false-negative results decreased only in the FES-PET/CT strategy by 13±15% compared with the standard work-up and by 17±16% compared with the FDG-PET/CT strategy.

The application of FES-PET/CT decreased the number of false positives by 58±12% compared with the standard work-up and by 44±15% compared with the FDG-PET/CT strategy, while in the FDG-PET/CT the false positives decreased by 26±22% compared with the standard work-up.

Economic analysis
-----------------

The total costs for the FES-PET/CT strategy were higher as compared with the standard work-up and the FDG-PET/CT strategy, although the total number of performed tests decreased in both PET/CT strategies as compared with the standard work-up (FES-PET/CT: 9±6% and FDG-PET/CT: 56±3%). The ICER to avoid an additional biopsy in the FES-PET/CT over the standard work-up was calculated at 12.1±3.4 thousand Euros. The FDG-PET/CT did not avoid biopsies and the costs were higher compared with the standard work-up, and it was a dominated strategy ([Table 4](#tbl4){ref-type="table"}).

Discussion
==========

The aim of this study was to evaluate the effect on the number of performed biopsies and costs associated with implementing PET/CT with FES or FDG as an upfront imaging test for diagnosing ER-positive MBC as compared with the standard work-up in women with symptoms. A previously applied and validated simulation model was expanded and revalidated for this study. The model proved to be sufficiently valid for reproducing the cohort results, which made it suitable for performing this economic evaluation. The PET/CT strategies yielded higher additional costs to diagnose MBC, although the total number of tests decreased as compared with the standard work-up. The number of false positives decreased in both PET/CT strategies. Biopsies were avoided and false negatives were decreased only in the FES-PET/CT strategy.

Novel diagnostic tests and therapies not only improved the survival rate among cancer patients in the last decades but also increased health-care expenditures ([@bib33]), so prior evaluation of costs and effects is warranted. Combined PET/ contrast-enhanced CT was suggested to provide a noninvasive evaluation of MBC in a single procedure ([@bib30]). This study showed that the PET/CT strategies decreased the number of imaging tests and thus could reduce the associated hospital visits, time off work and time to diagnosis.

The FES-PET/CT strategy decreased the number of false-negative diagnoses that could avoid potential delay in treatment and relief of symptoms. In addition, the FES-PET/CT strategy decreased the number of obtained biopsies and thus the number of painful and invasive episodes for patients. The sensitivity of FES-PET/CT is limited by several factors, including background uptake, ER expression levels in the tumour and the size of the tumour relative to the resolution of the PET camera. In our study, patients with initially ER-positive breast cancer underwent FES-PET only in case they presented with symptoms suggestive for metastatic recurrence. Modern PET cameras have a spatial resolution that can be as high as 2--4 mm, provided that the lesion has sufficient ER expression and is not obscured by the uptake of the organ it is located in (i.e., liver). As it is unlikely that a lesion smaller than the spatial resolution of the PET camera would cause actual symptoms, it seems unlikely that resolution limitations of PET has a significant impact on its sensitivity in this study.

PET/CT strategies reduced the number of false-positive imaging tests and the associated distress on patients. A false positive could as well generate additional diagnostic costs in terms of further imaging and biopsy testing to elucidate metastatic status or even unnecessary treatment. Furthermore, FES-PET/CT may guide therapeutic decision making ([@bib38]) as it provided insights in ER status and potential heterogeneity herein ([@bib25]; [@bib19]; [@bib38]), and thus could reduce costs resulting from ineffective therapy.

A recent economic evaluation concluded that PET/CT was more effective in terms of generated quality-adjusted life years (QALYs) for true positives, false positives and true negatives than the standard work-up for diagnosing MBC, and the ICER per QALY was 29.700 pounds (∼37.868 Euros) in a UK setting ([@bib1]). In our study, both PET/CT strategies generated less false positives and the FES-PET/CT generated less false negatives, but the ICER was calculated per avoided biopsy (ɛ12.100±3.400).

Although the simulation model reproduced the data in the validation cohort sufficiently, some differences were observed in the number of diagnosed bone MBCs and staging tests. A possible explanation might be that the cohort described by [@bib20] included patients irrespective of their ER status. ER-positive primary breast cancers showed tendency to give more often a first relapse to the bone; however, the reported numbers (35--68%) were not significantly different than the estimates in the simulation ([@bib36]). Other potential explanation could be the variation between clinical guidelines and self-reported actual practice that was partly owing to the time gap between developing the model and the validation cohort follow-up.

A limitation of this study was that the main evaluated outcome was avoided biopsies and other outcomes such as QALY and survival were not studied. Our study showed that FES-PET/CT could potentially have a positive impact on quality of life by decreasing the delay in relief of MBC symptoms and the negative effect on patients\' health resulting from a biopsy or false positive. FES-PET/CT could provide more information regarding metastatic recurrence than conventional approach ([@bib25]; [@bib19]; [@bib38]), and might have added value in therapy selection, individualised treatment and follow-up resulting in increase of survival. However, the impact of FES-PET/CT on treatment selection cannot yet be expressed in life years saved or QALYs, as the data for such an estimate are lacking.

Only ER-positive patients were considered, in which FES-PET/CT performs with a higher sensitivity. The ER status of the primary tumour and its probability to change over time should be further investigated, as it could have impact on proper patient and treatment selection and thus affect costs. A limitation of the FES-PET/CT strategy was that when a biopsy was avoided, no information on the status of other tumour receptors (i.e., HER2 status) was obtained. As HER2 status of the metastatic disease is of clinical relevance for the application of targeted therapy, the HER2 expression could be determined by PET imaging with ^89^Zr-trastuzumab ([@bib10]), which in contrast to biopsy would give information about the HER2 status in all lesions in the patient. Further study will have to point out whether adding this marker would be cost effective particularly from a clinical perspective. Another limitation was the follow-up period that was simulated for only 5 years owing to the lack of data regarding metastatic recurrence after that period.

Conclusions
===========

The application of upfront PET/CT with FES and FDG in MBC patients comes at additional costs. The number of performed biopsies was lower in the FES-PET/CT strategy at an ICER of 12.1±3.4 thousand Euro, whereas the FDG-PET/CT did not reduce the number of performed biopsies and was more expensive. Whether the FES-PET/CT strategy has additional benefits for patients in terms of therapy management has to be evaluated in clinical studies.

As FES-PET/CT could guide treatment selection and thus potentially affect cost effectiveness by avoiding ineffective therapies, its impact on treatment decision making in first line MBC should be further addressed.
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![**Structure of the MBCSIM simulation model for the standard work-up.** Women enter the simulation with bone, lung, liver and/or brain symptoms. The triangles indicate questions with output indicators Y=yes and N=no. The squares indicate imaging tests with output indicators, + denotes positive, − denotes negative and ± denotes inconclusive.](bjc2015138f1){#fig1}

![**Structure of the MBCSIM simulation model for the FES-PET/CT strategy.** Women enter the simulation with bone, lung, liver and/or brain symptoms. The triangles indicate questions with output indicators Y=yes and N=no. The squares indicate imaging tests with output indicators, + denotes positive, − denotes negative and ± denotes inconclusive. In case of multimodality imaging (i.e., FES-PET and CT), each individual modality can have these three outcomes, leading to nine possible outcomes for the combined modality (i.e., FES-PET/CT).](bjc2015138f2){#fig2}

![**Structure of the MBCSIM simulation model for the FDG-PET/CT strategy.** Women enter the simulation with bone, lung, liver and/or brain symptoms. The triangles indicate questions with output indicators Y=yes and N=no. The squares indicate imaging tests with output indicators, + denotes positive, − denotes negative and ± denotes inconclusive. In case of multimodality imaging (i.e., FDG-PET and CT), each individual modality can have these three outcomes, leading to nine possible outcomes for the combined modality (i.e., FDG-PET/CT).](bjc2015138f3){#fig3}

###### Parameters of the simulation model

                                                    Baseline estimate (%)   Minimum estimate (%)   Maximum estimate (%)       Reference
  ------------------------------------------------ ----------------------- ---------------------- ---------------------- -------------------
  **Risk to develop MBC**                                                                                                
  1st Year                                                   1.2                    1.0                    1.5                [@bib20]
  2nd Year                                                   2.9                    2.5                    3.3                     
  3rd Year                                                   2.7                    2.3                    3.1                     
  4th Year                                                   1.9                    1.6                    2.3                     
  5th Year                                                   1.6                    1.3                    1.9                     
  **Distribution of location of MBC**                                                                                    
  Bone                                                       46                      25                     61                [@bib20]
  Lung                                                       40                      26                     60                     
  Brain                                                      13                      7                      28                     
  Liver                                                      32                      24                     49                     
  **Probability of symptoms suggestive for MBC**                                                                         
  Bone                                                      10.0                    8.1                    11.8           [@bib34]; [@bib4]
  Lung                                                       3.0                    2.3                    3.4                     
  Brain                                                      2.0                    1.8                    2.7                     
  Liver                                                      1.0                    0.8                    1.1                     
  Probability of inconclusive biopsy                         20                      10                     30             Expert opinion
  Probability of inconclusive imaging                        10                      5                      15             Expert opinion

Abbreviation: MBC=metastatic breast cancer.

###### Sensitivity and specificity percentages and costs of imaging tests based on location of the metastatic breast cancer

                                            Bone            Lung          Liver           Brain                           Costs in ɛ ([@bib29])                      Reference
  ------------------------------------ --------------- -------------- -------------- --------------- --------------------------------------------------------------- -------------------------------------------------------------------------
  **Sensitivity**                                                                                                                                                    
  Bone scintigraphy                      80 (67--93)         NA             NA             NA                                      135                               ([@bib15])
  X-ray                                  61 (57--66)    74 (67--80)         NA             NA                                      47                                ([@bib22], [@bib27])
  Magnetic resonance imaging             94 (92--96)         NA        81 (76--86)     96 (84--99)    251[a](#t2-fn3){ref-type="fn"}/199[b](#t2-fn4){ref-type="fn"}  ([@bib39]; [@bib5]; [@bib9])
  Ultrasound                                 NA              NA        63 (25--87)         NA                                      52                                ([@bib9])
  Computed tomography                    67 (48--80)    94 (91--96)    97 (89--100)    86 (71--93)                                 199                               ([@bib7]; [@bib22], [@bib27], [@bib35])
  FES-PET[c](#t2-fn5){ref-type="fn"}    91 (88--100)    90 (82--97)    20 (10--30)     46 (40--52)                                1.505                              Expert opinion
  FDG-PET                                90 (88--96)    90 (88--96)    90 (88--96)     50 (40--60)                                1.505                              ([@bib32]; [@bib13];[@bib8]; [@bib26]), Expert opinion
  **Specificity**                                                                                                                                                    
  Bone scintigraphy                     86 (68--100)         NA             NA             NA                                                                        ([@bib15])
  X-ray                                 100 (99--100)   91 (91--92)         NA             NA                                                                        ([@bib22], [@bib27])
  Magnetic resonance imaging            89 (76--100)         NA        97 (94--99)     62 (48--76)                                                                   ([@bib39]; [@bib5]; [@bib9])
  Ultrasound                                 NA              NA        98 (96--100)        NA                                                                        ([@bib9])
  Computed tomography                    95 (80--95)    90 (90--100)   76 (68--84)    100 (92--100)                                                                  ([@bib22], [@bib16]; [@bib27], [@bib35])
  FES-PET[c](#t2-fn5){ref-type="fn"}    99 (98--100)    99 (98--100)   99 (98--100)   99 (98--100)                                                                   Expert opinion
  FDG-PET                                81 (71--95)    81 (71--95)    81 (71--95)     50 (40--60)                                                                   ([@bib13]; [@bib32]; [@bib8]; [@bib26]), Expert opinion, Expert opinion

Abbreviations: ER=oestrogen receptor; FDG=2-\[^18^F\]fluoro-2-deoxy-[D]{.smallcaps}-glucose; FES=16*α*-\[^18^F\]fluoro-17*β*-oestradiol; MRI=magnetic resonance imaging; NA=not applicable; PET=positron emission tomography.

Listed are estimated averages (95% confidence interval).

Price per bone MRI.

Price per brain/liver MRI.

The sensitivity and specificity values presented are relevant for ER-positive patients only.

###### Validation of the MBCSIM model in 108 ER-positive breast cancer patients for a follow-up period of 5 years

                               Validation database   Simulation (mean±s.d.)
  --------------------------- --------------------- ------------------------
  **Initial imaging tests**                         
                                       116                 104.0±6.5
  BS and X-bone                        53                   52.2±3.8
  MRI bone                              8                   15.3±2.2
  FDG-PET/CT                            3                   1.2±0.3
  X-ray lung                           31                   16.9±0.8
  CT lung/liver                         7                   2.0±0.4
  Ultrasound liver                      7                   7.0±0.3
  MRI liver                             0                   0.2±0.1
  MRI brain                             7                   9.2±2.5
  FES-PET/CT                            0                   0.0±0.0
  **Staging tests**                                 
                                       13                   17.9±1.3
  CT lung+CT liver                      5                   11.3±1.0
  BS+CT lung+CT liver                   8                   6.6±0.9
  **Biopsy tests**                                  
                                       18                   20.3±1.5
  Bone                                  6                   7.4±1.0
  Lung                                 10                   5.6±0.5
  Liver                                 0                   3.3±0.2
  Brain                                 2                   4.0±1.0
  **MBCs found**                                    
                                       14                   10.2±1.0
  Bone                                  8                   3.7±0.6
  Lung                                  3                   2.7±0.3
  Liver                                 2                   2.6±0.2
  Brain                                 1                   1.2±0.3

Abbreviations: BS, bone scan; CT=computed tomography; ER=oestrogen receptor; FDG=2-\[^18^F\]fluoro-2-deoxy-[D]{.smallcaps}-glucose; FES=16*α*-\[^18^F\]fluoro-17*β*-oestradiol; MBC=metastatic breast cancer; MBCSIM, metastatic breast cancer simulation; MRI=magnetic resonance imaging; PET=positron emission tomography.

###### Simulation outcomes for the standard work-up, FES-PET/CT and FDG-PET/CT strategies for a follow-up period of 5 years with 10 sets of data for 5073 women for 20 simulation rounds

                               Standard     FES-PET/CT                 FDG-PET/CT
  -------------------------- ------------- ------------- ---------------------------------------
  Initial imaging tests       963.19±60.0   1030.5±39.5                493.5±28.7
  Staging tests               165.4±12.5      0.0±0.0                    0.0±0.0
  Biopsy tests                188.4±14.3    114.7±14.7                 260.4±21.5
  MBCs found                   94.7±8.9     107.0±10.5                  91.2±8.8
  False-positive tests        103.9±24.4     43.1±8.0                   76.4±14.8
  Total costs × ɛ1000           232±15        1124±43                    652±35
  Additional costs × ɛ1000        NA          892±45                     420±38
  Saved biopsies                  NA         73.7±20.5                (-71.9±14.8)
  ICER × ɛ1000                    NA         12.1±3.4     (-5.8±2.2)[a](#t4-fn2){ref-type="fn"}

Abbreviations: CT=computed tomography; ER=oestrogen receptor; FDG=2-\[^18^F\]fluoro-2-deoxy-[D]{.smallcaps}-glucose; FES=16*α*-\[^18^F\]fluoro-17*β*-oestradiol; ICER=incremental cost-effectiveness ratio; MBC=metastatic breast cancer; MRI=magnetic resonance imaging; PET=positron emission tomography.

The ICER of the FDG-PET/CT over the standard work-up per avoided biopsy was negative as the costs were higher and there were no avoided biopsies (i.e., the health effect was negative).

[^1]: These authors contributed equally to this work.
